

SB0986/193327/1

BY: Finance Committee

AMENDMENTS TO SENATE BILL 986
(First Reading File Bill)

AMENDMENT NO. 1

On page 1, strike beginning with “, wholesale” in line 4 down through “provider,” in line 6; in line 6, after “certain” insert “direct or indirect”; and in line 9, after “Act,” insert “requiring the Maryland Prescription Drug Affordability Board to conduct a study of the 340B Program.”

AMENDMENT NO. 2

On page 3, strike beginning with “THIS” in line 12 down through “(C)” in line 18; in lines 8 and 23, in each instance, strike “(D)” and substitute “(C)”; and in line 24, strike “AN ENTITY SUBJECT TO THIS SECTION” and substitute “A 340B MANUFACTURER”.

On page 4, in line 3, strike “AN ENTITY SUBJECT TO THIS SECTION” and substitute “A 340B MANUFACTURER”; in lines 6, 7, and 12, strike “(E)”, “(I)”, and “(II)”, respectively, and substitute “(D)”, “1.”, and “2. A.”, respectively; in lines 6, 17, and 20, in each instance, strike “(D)” and substitute “(C)”; in line 6, after “(1)” insert “(I)”; in line 12, strike “SHALL” and substitute “IF THE ALLEGED VIOLATION WAS COMMITTED BY A PERSON THAT IS LICENSED OR PERMITTED BY THE BOARD, SHALL”; in the same line, strike “JOINTLY OR SEPARATELY”; in line 14, after “GENERAL” insert “; OR”

B. IF THE ALLEGED VIOLATION WAS COMMITTED BY A PERSON THAT IS NOT LICENSED OR PERMITTED BY THE BOARD, SHALL BE INVESTIGATED BY THE CONSUMER PROTECTION DIVISION OF THE OFFICE OF THE ATTORNEY GENERAL”;

after line 14, insert:

“(II) AS PART OF AN INVESTIGATION CONDUCTED UNDER PARAGRAPH (1)(I)2 OF THIS SUBSECTION, THE BOARD OR THE CONSUMER PROTECTION DIVISION OF THE OFFICE OF THE ATTORNEY GENERAL MAY INVESTIGATE AN AFFILIATE OR A CONTRACTOR OF THE 340B MANUFACTURER, INCLUDING A WHOLESALER OR THIRD-PARTY LOGISTICS PROVIDER.”;

in line 17, strike “\$50,000” and substitute “\$5,000”; in line 25, strike “(D)” and substitute “(C)”; after line 25, insert:

“SECTION 2. AND BE IT FURTHER ENACTED, That:

(a) The Maryland Prescription Drug Affordability Board, in consultation with the Maryland Department of Health:

(1) shall conduct a study on:

(i) the current implementation and scope of the 340B Program in the State;

(ii) the implementation and impact of the implementation of Section 1 of this Act; and

(iii) the finances of the Program in the State, including how covered entities reinvest savings realized from the Program; and

(2) may require covered entities and 340B manufacturers to report information as necessary to complete the study.

SB0986/193327/01 **Finance Committee**
Amendments to SB 986
Page 3 of 3

(b) On or before July 1, 2026, the Maryland Prescription Drug Affordability Board shall report its findings and recommendations from the study to the Senate Finance Committee and the House Health and Government Operations Committee, in accordance with § 2-1257 of the State Government Article.”;

and in line 26, strike “2.” and substitute “3.”.